Guangdong Hybribio Biotech Co Ltd (300639) fair value: what the stock is really worth
As of Sep 22, 2026: fair value of Guangdong Hybribio Biotech Co Ltd ¥6.34, price ¥6.17, upside +2.8%, quality 60 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Guangdong Hybribio Biotech Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range ¥4.38 – ¥15.84 · fair‑value band ¥4.26 – ¥9.15 · the ¥6.17 price screens below the ¥6.34 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Follow Guangdong Hybribio Biotech Co in your weekly email
Every Wednesday you see whether Guangdong Hybribio Biotech Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal.
Show more
Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal. The company also offers STD real time PCR kits; hepatitis B virus real-time PCR kits and thalassemia genoarray diagnostic kits; hearing loss susceptibility genoarray diagnostic kits; COVID-19 real-time PCR kits; and devices/instruments, including automated nucleic acid extraction, automatic medical PCR analysis, flow-through hybridization, auto DNA extraction, and fluorescent quantitative detection systems, as well as after-sales technical service support. Its products are used in the fields of national screening, clinical, and research purposes. The company operates in the Asia Pacific, the South East Asia, the Middle East, Europe, Africa, and South America. The company was founded in 2003 and is based in Chaozhou, China.
Stock analysis
Guangdong Hybribio Biotech Co Ltd (300639) currently trades at ¥6.17, while our model-based Fair Value estimate is ¥6.34, implying the stock looks roughly 2.7% fairly valued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ¥6.26 per share, and 5 of the 10 models we run sit above the ¥6.17 price.
Bear case: the Multiples group reads lowest at ¥1.62, and 5 of the 10 models stay below the price. Evidence for this calculation is low.
Scenario range: ¥4.26 (bear) to ¥9.15 (bull), the price of ¥6.17 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Guangdong Hybribio Biotech Co Ltd reported revenue of 670M CNY in FY2025 versus 2.7B CNY in FY2021, a compound −29.3%/yr. Reported net income was −131M CNY in FY2025.
Key figures
Market cap 4.0B CNY (≈ $596M) · P/S ratio 5.24 · EPS (TTM) ¥−0.1700 · Dividend yield 0.1% · Net margin −19.6% · Return on equity −3.8% · Return on assets (EBIT) 7.5% · Operating margin −20.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (medium confidence).
What moves the price
The share trades about 30% below its 52-week high and 26% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 3%, 300639 screens cheaper than that median.
Fair Value models
Bear ¥4.26Fair Value ¥6.34Bull ¥9.15
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.23/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−17.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−50.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.1%
Start year 2020 (pandemic). Over 10 years: +6.9% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
34.6% (2020) → −20.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−0.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −2.1% a year for the price.
Compare Guangdong Hybribio Biotech Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 142 stocks
Beats the industry median on 6/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score60 · Above median
Fair Value upside+3% · Above median
Profitability
Return on assets−2% · Below median
Net margin (TTM)−16% · Bottom 25%
Operating margin (TTM)−21% · Bottom 25%
Growth and dividend
Revenue growth−6% · Bottom 25%
Dividend yield (TTM)0.1% · Bottom 25%
Balance sheet
Debt / equity0.02× · Below median
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Guangdong Hybribio Biotech Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/300639
Frequently asked questions
Is Guangdong Hybribio Biotech Co Ltd (300639) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of ¥6.34 versus a price of ¥6.17, about +3% upside (fairly valued).
What is the fair value of 300639?
Our model-based fair value for Guangdong Hybribio Biotech Co Ltd is ¥6.34 (as of Sep 23, 2026), built from audited fundamentals. The current price: ¥6.17.
What is the quality score of 300639?
Guangdong Hybribio Biotech Co Ltd has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Guangdong Hybribio Biotech Co Ltd (300639)?
Our model-based price target is the fair value of ¥6.34 (as of Sep 23, 2026) from 10 valuation models. Cautious scenario ¥4.26, optimistic scenario ¥9.15. It is a calculation from audited fundamentals, not an analyst target.
What is the Guangdong Hybribio Biotech Co Ltd stock forecast for 2026?
Our models put fair value at ¥6.34, about +3% upside versus a price of ¥6.17 (fairly valued). Cautious scenario ¥4.26, optimistic scenario ¥9.15. The calculation is refreshed regularly with new filings.
What is the revenue of Guangdong Hybribio Biotech Co Ltd (300639)?
Guangdong Hybribio Biotech Co Ltd reported trailing-twelve-month revenue of about 661M CNY (latest available figure, as of Sep 23, 2026).
Does Guangdong Hybribio Biotech Co Ltd pay a dividend?
Guangdong Hybribio Biotech Co Ltd currently shows a dividend yield of about 0.10% relative to its recent price (as of Sep 23, 2026).
What growth is priced into Guangdong Hybribio Biotech Co Ltd (300639)?
For today's price to be fair in a discounted-cash-flow model, Guangdong Hybribio Biotech Co Ltd would have to grow free cash flow by -0.5 % per year for five years (discount rate 9.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -13.1 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of 300639 use?
Our models discount Guangdong Hybribio Biotech Co Ltd at 9.1 %: a base by market capitalisation (mid), damped by beta 0.47, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Guangdong Hybribio Biotech Co Ltd that is -0.5 % per year a year over ten years, using the same discount rate (9.1 %) and the same formula as our fair value.
How much growth has Guangdong Hybribio Biotech Co Ltd (300639) delivered so far?
Over the past 5 years revenue at Guangdong Hybribio Biotech Co Ltd grew -13.1 % a year. The price currently implies -0.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Guangdong Hybribio Biotech Co Ltd (300639) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Guangdong Hybribio Biotech Co Ltd (-0.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Guangdong Hybribio Biotech Co Ltd (300639)?
The free-cash-flow yield on the price is 6.25 %: that much free cash flow Guangdong Hybribio Biotech Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Guangdong Hybribio Biotech Co Ltd (300639)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Guangdong Hybribio Biotech Co Ltd it is ¥6.34 per share (as of Sep 23, 2026), against a price of ¥6.17. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is Guangdong Hybribio Biotech Co Ltd stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 300639 trades below its calculated fair value: price ¥6.17, fair value ¥6.34, a gap of about +3% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300639?
No. The price is what the market pays today (¥6.17); the fair value is what the company's own numbers justify (¥6.34). For Guangdong Hybribio Biotech Co Ltd the two are ¥0.1700 per share apart. That gap is exactly why we show both numbers side by side.
How much is Guangdong Hybribio Biotech Co Ltd worth?
The market values Guangdong Hybribio Biotech Co Ltd at about 4.0B CNY (market capitalisation, as of Sep 23, 2026). Per share that is ¥6.17; our models calculate a fair value of ¥6.34 per share.
What do the bullish and bearish scenarios say about 300639?
Our models span a range for Guangdong Hybribio Biotech Co Ltd: cautious scenario ¥4.26, base ¥6.34, optimistic ¥9.15 per share (as of Sep 23, 2026, price ¥6.17). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Guangdong Hybribio Biotech Co Ltd (300639)?
Balance-sheet figures for Guangdong Hybribio Biotech Co Ltd (as of Sep 23, 2026): return on equity −3.8%, debt of 0.02 per unit of equity. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is 300639 from its 52-week high?
Guangdong Hybribio Biotech Co Ltd trades at ¥6.17, about 30% below its 52-week high of ¥8.81 and 26% above the low of ¥4.88 (as of Sep 22, 2026). Distance from the high says nothing about value: that is what the fair value of ¥6.34 is for.
Which stocks are comparable to Guangdong Hybribio Biotech Co Ltd?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Guangdong Hybribio Biotech Co Ltd stock attractive at the current price?
The data as of Sep 23, 2026: price ¥6.17, calculated fair value ¥6.34 (+3%), Quality Score 60/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300639 calculated?
We run Guangdong Hybribio Biotech Co Ltd through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥6.34, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Guangdong Hybribio Biotech Co Ltd currently trades 3 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Guangdong Hybribio Biotech Co Ltd (300639)?
The closing price on Sep 22, 2026 was ¥6.17. Our model-based fair value is ¥6.34, about +3% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Guangdong Hybribio Biotech Co Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (¥4.26 to ¥9.15) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Where does the earnings growth of Guangdong Hybribio Biotech Co Ltd (300639) come from?
Earnings per share at Guangdong Hybribio Biotech Co Ltd grew +34.4 % a year from 2013 to 2024. Broken into its drivers: revenue per share +29.3 %, EBIT margin +4.6 %, tax rate −0.1 %, residual (interest, one-offs) −0.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Guangdong Hybribio Biotech Co Ltd
How large is the market capitalisation of Guangdong Hybribio Biotech Co Ltd (300639)?
The market capitalisation of Guangdong Hybribio Biotech Co Ltd is 4.0B CNY (≈ $596M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Guangdong Hybribio Biotech Co Ltd (300639)?
The price-to-sales ratio of Guangdong Hybribio Biotech Co Ltd is 5.24 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Guangdong Hybribio Biotech Co Ltd (300639)?
Earnings per share at Guangdong Hybribio Biotech Co Ltd are ¥−0.1700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Guangdong Hybribio Biotech Co Ltd (300639)?
The dividend yield of Guangdong Hybribio Biotech Co Ltd is 0.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Guangdong Hybribio Biotech Co Ltd (300639)?
The net margin of Guangdong Hybribio Biotech Co Ltd is −19.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Guangdong Hybribio Biotech Co Ltd (300639)?
The return on equity (ROE) of Guangdong Hybribio Biotech Co Ltd is −3.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Guangdong Hybribio Biotech Co Ltd (300639)?
On an EBIT basis the return on assets of Guangdong Hybribio Biotech Co Ltd is 7.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Guangdong Hybribio Biotech Co Ltd (300639)?
The operating margin of Guangdong Hybribio Biotech Co Ltd is −20.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Guangdong Hybribio Biotech Co Ltd (300639)?
Revenue at Guangdong Hybribio Biotech Co Ltd is growing −6.1% versus a year earlier (3y avg −50.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Guangdong Hybribio Biotech Co Ltd (300639)?
Earnings per share at Guangdong Hybribio Biotech Co Ltd are growing −90.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Guangdong Hybribio Biotech Co Ltd (300639) hold?
Guangdong Hybribio Biotech Co Ltd holds more cash than debt, 633M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Guangdong Hybribio Biotech Co Ltd in the live analysis
One click puts Guangdong Hybribio Biotech Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
